Parkinson Disease: all 4,583 studies
Page 44 of 46. Open to participants first (1,097), then studies with results posted, then the rest; newest registration first within each.
- Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease PatientsCompletedNCT00642928Phase 2
- Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)CompletedNCT00642889Phase 3
- Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's DiseaseWithdrawnNCT00640952Not applicable
- Deep Brain Stimulation and Digestive SymptomatologyCompletedNCT00639275
- Motor Cortex Stimulation for Parkinson's DiseaseCompletedNCT00637260Not applicable
- Long-Term Effects of Amantadine in Parkinsonian (AMANDYSK)CompletedNCT00632762Phase 4
- Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)CompletedNCT00630500Phase 2
- Clinical Trial on the Effectiveness of Traditional Chinese Medicinal Mixture in Parkinson DiseaseStatus unknownNCT00629161Phase 2/3
- Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to LevodopaCompletedNCT00627640Phase 3
- Phase I/II Study of the Safety, Efficacy and Dose Evaluation of ProSavin for the Treatment of Bilateral Idiopathic Parkinson's DiseaseCompletedNCT00627588Phase 1/2
- Repetitive Transcranial Stimulation (r-TMS) Treatment for Patients With Parkinson's DiseaseCompletedNCT00625300Phase 2
- Compassionate Use Study of Pergolide in Patients With Parkinson's DiseaseNo longer availableNCT00624741
- The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's DiseaseCompletedNCT00623324Phase 2
- Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)CompletedNCT00617019
- Special Survey on PD Patients With Renal DysfunctionCompletedNCT00613756
- Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy SubjectsTerminatedNCT00612872Phase 1
- Study of Tai Chi Exercise and Balance in Persons With Parkinson's DiseaseCompletedNCT00611481Phase 2
- Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa TherapyCompletedNCT00610103Phase 2
- Dexmedetomidine Effects on Microelectrode Recording in Deep Brain StimulationWithdrawnNCT00608231Phase 2/3
- MOTION, Safinamide in Early IPD, as add-on to Dopamine AgonistCompletedNCT00605683Phase 3
- Study to Evaluate SYN115 in Parkinson's DiseaseCompletedNCT00605553Phase 2
- A Longitudinal Observational Follow-up of the PRECEPT Study CohortStatus unknownNCT00605163
- Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing OffWithdrawnNCT00601978Phase 4
- Perioperative Treatment of Parkinsonian Patients With Parenteral AmantadineTerminatedNCT00600093Phase 2
- Deep Brain Stimulation in Patients With Parkinson's DiseaseCompletedNCT00586079Not applicable
- Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's DiseaseWithdrawnNCT00584090Phase 4
- Keppra IV for the Treatment of Motor Fluctuations in Parkinson's DiseaseWithdrawnNCT00584025Phase 4
- Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopaCompletedNCT00582673Phase 2
- Clinical Effects of Vitamin D Repletion in Patients With Parkinson's DiseaseTerminatedNCT00571285Phase 4
- PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride BindingTerminatedNCT00562198Phase 2
- Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's DiseaseCompletedNCT00559871Phase 2
- Motor Cortex Reward Signaling in Parkinson DiseaseCompletedNCT00558766
- Efficacy, Safety, and Pharmacokinetics/Pharmacodynamic Study of L-Dopa/Carbidopa To Treat Parkinson's DiseaseCompletedNCT00558337Phase 2
- Development of Cognitive Assessment Tools in Parkinson DiseaseCompletedNCT00556764Early Phase 1
- Deep Brain Stimulation to Treat Symptoms of Parkinson's DiseaseCompletedNCT00552474Not applicable
- PET Study of the Nicotinic Receptors in HumanTerminatedNCT00543322
- Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's DiseaseCompletedNCT00539214
- Body Weight Gain, Parkinson, Subthalamic StimulationCompletedNCT00529724Phase 2
- A Pilot, Randomized Controlled Trial of Group Visits for Persons With Parkinson's DiseaseCompletedNCT00528086
- Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging StudyCompletedNCT00524914Not applicable
- Integrated Multidisciplinary Care for Parkinson's Disease: a Controlled TrialCompletedNCT00518791Phase 3
- Reduction of Falls in the Elderly - Parkinson's DiseaseCompletedNCT00518648Phase 3
- Neuroimaging Studies of Depression in Parkinson's DiseaseCompletedNCT00518258
- A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's DiseaseCompletedNCT00517842Not applicable
- Study of the Modification of the Pharmacokinetic Profile of Levodopa by the Fiber Plantago Ovata HuskCompletedNCT00507715Phase 1
- A Study of MK0657 in Parkinson's Disease Patients (0657-006)CompletedNCT00505843Phase 1
- The APOS System: Effects on Gait, Mobility and QOL in Patients With Parkinson's DiseaseStatus unknownNCT00498758Phase 2
- PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral TabletsCompletedNCT00491998Phase 1/2
- Enteric Nervous System in Parkinson's DiseaseCompletedNCT00491062Not applicable
- Improve Speech Using an In-the-ear Device in Parkinson's DiseaseCompletedNCT00488657Phase 1
- Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer DiseaseCompletedNCT00480701Phase 2
- Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's DiseaseTerminatedNCT00477802Phase 4
- Cognitive Impairment in Parkinson's Disease Categorised in Accordance to Motor SymptomsCompletedNCT00476372
- Low Dose Apomorphine and ParkinsonismWithdrawnNCT00472355Phase 2
- Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor PatientsCompletedNCT00468078Phase 3
- Characteristics of Parkinson s Disease Associated With the LRRK-2 Gene MutationTerminatedNCT00467090
- European Compliance Study in Parkinson's DiseaseCompletedNCT00466739
- Research of Biomarkers in Parkinson DiseaseCompletedNCT00465790
- Ramelteon (ROZEREM) in the Treatment of Sleep Disturbances Associated With Parkinson's DiseaseTerminatedNCT00462254Phase 4
- Study to Evaluate Initiation of Stalevo in Early Wearing-offCompletedNCT00462007Phase 4
- Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson's Disease PatientsCompletedNCT00461942Phase 2
- A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy SubjectsCompletedNCT00460954
- Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of RopiniroleCompletedNCT00460148Phase 2
- Caffeine for Excessive Daytime Somnolence in Parkinson's DiseaseCompletedNCT00459420Phase 2/3
- 12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/CarbodopaCompletedNCT00456794Phase 2
- 12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/CarbidopaCompletedNCT00456586Phase 2
- A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaCompletedNCT00455507Phase 2
- BIIB014 Phase 2a MonotherapyWithdrawnNCT00451815Phase 2
- The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor FluctuationsWithdrawnNCT00451633Phase 2
- Medication Review in Patients on Anti-parkinson TherapyCompletedNCT00443768
- Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's DiseaseCompletedNCT00442780Phase 2
- Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's DiseaseCompletedNCT00438607Phase 2
- Sequence Effect in Parkinson's DiseaseCompletedNCT00431366
- Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease PatientsTerminatedNCT00427674Phase 1
- Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous InfusionCompletedNCT00408915Phase 3
- A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and EfficacyCompletedNCT00407212Phase 1/2
- An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.CompletedNCT00407095Phase 3
- SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor FluctuationsCompletedNCT00406588Phase 3
- Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson DiseaseCompletedNCT00404170Phase 2
- A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's DiseaseCompletedNCT00399477Phase 4
- Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons DiseaseCompletedNCT00397696Phase 2
- ALTROPANE® SPECT Imaging in Patients With Parkinson DiseaseCompletedNCT00397228Phase 2
- Motor Skill Learning in People With Parkinson's DiseaseCompletedNCT00396942
- Comparison of Modafinil and Methylphenidate in Treatment of Excessive Daytime Sleepiness in Patients With Parkinson's DiseaseWithdrawnNCT00393562Not applicable
- Exercise Study For People With Parkinson's DiseaseStatus unknownNCT00387218Not applicable
- A Study Evaluating Potential Screening Tools for Detecting Parkinson DiseaseStatus unknownNCT00387075Phase 2
- Assessing the Role of Exercise Intensity in Slowing Disease Progression in Early Parkinson's DiseaseStatus unknownNCT00385073
- Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopaCompletedNCT00381472Phase 3
- Parkinson's Disease Evaluated by PET and the Effect of MemantineCompletedNCT00375778Not applicable
- COMT Polymorphism and Entacapone EfficacyCompletedNCT00373087Phase 4
- Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian SyndromesCompletedNCT00368199
- Parkinson's Genes and Environment StudyCompletedNCT00367900
- Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson'sCompletedNCT00363727Phase 3
- DYSCAR: Characterization of DystoniaCompletedNCT00361465
- Electronic Compliance Monitoring in Parkinson's DiseaseCompletedNCT00361205Not applicable
- Psychiatric and Cognitive Manifestations of Parkinson's DiseaseCompletedNCT00360633
- Methylphenidate and Parkinson's DiseaseCompletedNCT00359723Phase 2
- Effects of Deep Brain Stimulation for the Treatment of Parkinson's DiseaseCompletedNCT00358189
- Sedation During Microelectrode Recordings Before Deep Brain Stimulation for Movement Disorders.Status unknownNCT00355927Not applicable
- Controlled Trial With Deep Brain Stimulation in Patients With Early Parkinson's DiseaseStatus unknownNCT00354133Phase 4